These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 9275269)
1. Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. Nijs HG; Tordoir DM; Schuurman JH; Kirkels WJ; Schröder FH J Med Screen; 1997; 4(2):102-6. PubMed ID: 9275269 [TBL] [Abstract][Full Text] [Related]
2. Why do men refuse or attend population-based screening for prostate cancer? Nijs HG; Essink-Bot ML; DeKoning HJ; Kirkels WJ; Schröder FH J Public Health Med; 2000 Sep; 22(3):312-6. PubMed ID: 11077903 [TBL] [Abstract][Full Text] [Related]
3. Can Flemish women in semi-rural areas be motivated to attend organized breast cancer screening? Van Hal G; Matthyssen M; Thibaut A; Weyler J Rev Epidemiol Sante Publique; 1999 Apr; 47(2):119-27. PubMed ID: 10367299 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of predictors of attendance for breast screening in inner London. Sutton S; Bickler G; Sancho-Aldridge J; Saidi G J Epidemiol Community Health; 1994 Feb; 48(1):65-73. PubMed ID: 8138773 [TBL] [Abstract][Full Text] [Related]
5. Factors related to non-attendance in a population based melanoma screening program. Bergenmar M; Törnberg S; Brandberg Y Psychooncology; 1997 Sep; 6(3):218-26. PubMed ID: 9313288 [TBL] [Abstract][Full Text] [Related]
6. European randomized study of screening for prostate cancer--the Rotterdam pilot studies. Shröder FH; Damhuis RA; Kirkels WJ; De Koning HJ; Kranse R; Nus HG; Blijenberg BG Int J Cancer; 1996 Jan; 65(2):145-51. PubMed ID: 8567109 [TBL] [Abstract][Full Text] [Related]
7. Compliance with biopsy recommendations of a prostate cancer risk calculator. van Vugt HA; Roobol MJ; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Steyerberg EW; Korfage I BJU Int; 2012 May; 109(10):1480-8. PubMed ID: 21933335 [TBL] [Abstract][Full Text] [Related]
8. Two distinct groups of non-attenders in an organized mammography screening program. Aro AR; de Koning HJ; Absetz P; Schreck M Breast Cancer Res Treat; 2001 Nov; 70(2):145-53. PubMed ID: 11768605 [TBL] [Abstract][Full Text] [Related]
9. The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients. García Figueredo I; Pereda-Meira CM; Morejón Morales A; Correoso Braña K; Candia MN; Zarut Portillo P; Chappé Pacheco M Medwave; 2016 Jul; 16(6):e6501. PubMed ID: 27532102 [TBL] [Abstract][Full Text] [Related]
10. Short-term effects of population-based screening for prostate cancer on health-related quality of life. Essink-Bot ML; de Koning HJ; Nijs HG; Kirkels WJ; van der Maas PJ; Schröder FH J Natl Cancer Inst; 1998 Jun; 90(12):925-31. PubMed ID: 9637143 [TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369 [TBL] [Abstract][Full Text] [Related]
12. A primary healthcare-based intervention to improve a Danish cervical cancer screening programme: a cluster randomised controlled trial. Jensen H; Svanholm H; Støvring H; Bro F J Epidemiol Community Health; 2009 Jul; 63(7):510-5. PubMed ID: 19228681 [TBL] [Abstract][Full Text] [Related]
13. Prevention and detection of prostate cancer: a pilot intervention in a resource--poor South African community. Matshela RF; Maree JE; van Belkum C Cancer Nurs; 2014; 37(3):189-97. PubMed ID: 23632472 [TBL] [Abstract][Full Text] [Related]
14. The impact of prostate cancer knowledge on cancer screening. Weinrich SP; Weinrich MC; Boyd MD; Atkinson C Oncol Nurs Forum; 1998 Apr; 25(3):527-34. PubMed ID: 9568607 [TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with participation in screening for colorectal cancer with faecal occult blood testing. Lindholm E; Berglund B; Haglind E; Kewenter J Scand J Gastroenterol; 1995 Feb; 30(2):171-6. PubMed ID: 7732341 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with non-participation of women in a breast cancer screening programme in a town in northern Italy. Donato F; Bollani A; Spiazzi R; Soldo M; Pasquale L; Monarca S; Lucini L; Nardi G J Epidemiol Community Health; 1991 Mar; 45(1):59-64. PubMed ID: 2045747 [TBL] [Abstract][Full Text] [Related]
18. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Schröder FH; Bangma CH; Roobol MJ Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712 [TBL] [Abstract][Full Text] [Related]
19. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. Park P; Simmons RK; Prevost AT; Griffin SJ BMC Public Health; 2008 Oct; 8():350. PubMed ID: 18840266 [TBL] [Abstract][Full Text] [Related]
20. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]